Renal biopsies, while painful, remain the gold standard for diagnosing and classifying lupus nephritis. But what if there are less-invasive methods? In this article, I highlight key abstracts exploring innovative approaches. https://t.co/ZInKmVS2Gn @RheumNow #ACR24

• Beyond the Needle: Redefining the Assessment of Lupus Nephritis | RheumNow

Upadacitinib in Behcet's disease - would be very much welcomed, and this open label 8 patient pilot from China is encouraging. We saw similar data for tofacitinib before @ARD_BMJ: https://t.co/YlAQVXpnTY JAKi (?generic) could be a fantastic option! #ACR24 ABST2515 @RheumNow https://t.co/65friNLUOK

• A pilot study of tofacitinib for refractory Behçet’s syndrome
• https://x.com/drdavidliew/status/1858481726164783377/photo/1

Post hoc analysis of SPIRIT H2H evaluated nail involvement as a measure of ttnt response in PsA. -Pts with nail involvement treated with IXE or ADA had higher SJC and TJC improvement vs those without involvement at W12, W24 and W52. -IXE achieved rapid response for DAPSA-LDA as… https://t.co/SR36qCthQo https://t.co/hI3tD5hATJ

• https://x.com/i/web/status/1858299028125212898
• https://x.com/AdelaCastro222/status/1858299028125212898/photo/1

My ramblings on the SELECT-GCA study and predictions of the place of upadacitinib in clinical practice in GCA are up now on RheumNow #ACR24 @RheumNow https://t.co/DR5VgVmdse

• SELECT-GCA: Efficacy and Safety of Upadacitinib | RheumNow

We saw evidence for JAK use in GCA this conference... what about IL-1 inhibition? Double-blind RCT: Anakinra vs. PBO w/ similar GC taper in GCA pt NO difference in relapse rate at 26, 52 wks despite addition of Anakinra @RheumNow #ACR24 Abst1699 https://t.co/gUb0gGJjTG

• https://x.com/Dr_Brian_MD/status/1858268878658514984/photo/1

VERY exciting SLE update from Fava et al. Machine learning used to generate urinary protein panel predictive of intra-renal inflammation BETTER than serum biomarkers C3, C4, dsDNA Also monitoring tool for renal response. Outstanding. @RheumNow #ACRbest #ACR24 https://t.co/YXgKrSU4UQ

• https://x.com/Dr_Brian_MD/status/1858272797983977838/photo/1
• https://x.com/Dr_Brian_MD/status/1858272797983977838/photo/1

Phase 2 RCT of MK2 inhibitor did not show clinical efficacy at week 12 in active AS pts compared to PBO. There are still unmet needs for additional therapeutics in pts with AS that not respond to current therapies. Abst#1760 #ACR24 @RheumNow https://t.co/cXv8HYr0Xr

• https://x.com/AdelaCastro222/status/1858263006217400826/photo/1
• https://x.com/AdelaCastro222/status/1858263006217400826/photo/1

Interesting comparative effectivness study, TOFA vs calcineurin inhibitors in MDA5-dermato Expansion of prior publication @NEJM that used historical controls: https://t.co/AzA8ybCqYH Encouraging data for JAKs in this disease; need proper trials #ACR24 @RheumNow Abstr#1736 https://t.co/BHVMZLu6Ip

• Tofacitinib in Amyopathic Dermatomyositis–Associated Interstitial Lung Disease …
• https://x.com/EBRheum/status/1858261077311529458/photo/1
• https://x.com/EBRheum/status/1858261077311529458/photo/1
• https://x.com/EBRheum/status/1858261077311529458/photo/1

Wu et al. MDA5-DM. Propensity-score cohort study. 672 patients. Tofacitinib vs CNI. Primary outcome 1 year death or lung transplant. HR 0.70 favouring tofacitinib. @RheumNow #ACR24 Abstr#1736 https://t.co/A0aHhp1q9c https://t.co/LbutJDBllr

• Effectiveness and Safety of Tofacitinib vs. Calcineurin Inhibitor in Interstiti…
• https://x.com/RichardPAConway/status/1858261329993212326/photo/1

Chinoy et al. Baricitinib in IIM. Delayed-start clinical trial. 15 patients. 14/15 improved at 24 weeks (the other withdrew). 50% vs 100% at week 12 (delayed start group initiation). Stats confuse me a bit here but promising. @RheumNow #ACR24 Abstr#1731 https://t.co/orewsxbPpL https://t.co/5AyRpYJdec

• Baricitinib in the Treatment of Adult Idiopathic Inflammatory Myopathy: A Rando…
• https://x.com/RichardPAConway/status/1858251010788991334/photo/1

📝Bimekizumab 160mg Q4 weeks in r-axSpA and nr-axSpA achieved substantial reductions in MRI inflammation at Wk 16 maintaining to Wk 52. -PBO‑switchers (started at week 16) reached similar levels of improvement as continuous BKZ pts at Wk 52. Abst#1757 #ACR24 @RheumNow https://t.co/m9sdAbFqI9

• https://x.com/AdelaCastro222/status/1858246229513400637/photo/1
• https://x.com/AdelaCastro222/status/1858246229513400637/photo/1

Frideres et al. Target trial emulation in RA-ILD. Primar outcome death or respiratory hospitialization. Abatacept (aHR 0.90), tocizilumab (aHR 0.93), tofacitinib (aHR 0.69) vs rituximab. @RheumNow #ACR24 Abstr#1713 https://t.co/fbE8xAnzQ2 https://t.co/uwzH8oAyAT

• Comparisons of Non-TNFi Biologic and Targeted Synthetic DMARDs in Rheumatoid Ar…
• https://x.com/RichardPAConway/status/1858242203380003024/photo/1

A picture is worth a thousand words—and so are the four abstracts behind it! At #ACR24, I highlight the benefits and risks of apremilast in #PsA. @RheumNow https://t.co/ospR0qEIsd

• Apremilast Benefits and Risks in PsA | RheumNow

de Boysson et al. RCT anakinra in GCA. 30 patients. Week 52 relapse 53% in anakinra vs 46% in placebo. @RheumNow #ACR24 Abstr#1699 https://t.co/sqDWUlkXAX

• https://x.com/RichardPAConway/status/1858227355447378085/photo/1

Subgroup data from SELECT GCA, overall reinforces overall message I was curious to see pts previously treated with TCZ; wonder if that selects for refractory phenotype - seems not to be the case Take home: encouraging data, no subgroup issues #ACR24 @RheumNow Abstr#1695 https://t.co/5iCLE6T4u3

• https://x.com/EBRheum/status/1858214520612917751/photo/1
• https://x.com/EBRheum/status/1858214520612917751/photo/1
• https://x.com/EBRheum/status/1858214520612917751/photo/1